Maternal effect on intelligence of fragile X males and females

D. L. Van Dyke, L. Weiss

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

If the mother is the fragile X gene carrier, her daughters (and sons) with the mutation are at high risk of mental retardation. If the father is the (clinically unaffected) carrier, his daughters are normal. This is strong evidence for a maternal effect. The decreased penetrance and variable expressivity in fra(X) offspring of carriers could be related, at least in part, to variable expression or availability of some maternal factor between pregnancies. We hypothesize a maternal effect in fra(X), with variability in intelligence of hererozygotes and hemizygotes mediated mainly by the maternal uterus or placenta by virtue of different patterns of lyonization in those tissues between pregnancies. If the mother is a carrier, the maternal placenta could develop with a skewed proportion of the normal or the fra(X) genetically active. Each female or male embryo could be exposed to very different environments with respect to genetic activity of the fra(X) chromosome, depending on the site of implantation within the uterus. If the father contributes the fra(X), the intrauterine environment is invariably normal and so are the daughters. Modifiers of the intrauterine effect could include lyonization patterns in tissues of the carrier fetus, and preferential inactivation of the paternal X in extra-embryonic tissues. The ultimate phenotype of the developing heterozygote and hemizygote may be determined by a threshold effect and interaction between the maternal genotype, the placental genotype, and the fetal genotype. The possibility of maternal effect is testable and has implications for treatment.

Original languageEnglish (US)
Pages (from-to)723-737
Number of pages15
JournalAmerican Journal of Medical Genetics
Volume23
Issue number1-2
StatePublished - 1986
Externally publishedYes

Fingerprint

Intelligence
Mothers
Nuclear Family
X Chromosome Inactivation
Hemizygote
Genotype
Fathers
Placenta
Uterus
Pregnancy
Penetrance
X Chromosome
Heterozygote
Intellectual Disability
Maternal Inheritance
Fetus
Embryonic Structures
Phenotype
Mutation
Genes

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Maternal effect on intelligence of fragile X males and females. / Van Dyke, D. L.; Weiss, L.

In: American Journal of Medical Genetics, Vol. 23, No. 1-2, 1986, p. 723-737.

Research output: Contribution to journalArticle

Van Dyke, DL & Weiss, L 1986, 'Maternal effect on intelligence of fragile X males and females', American Journal of Medical Genetics, vol. 23, no. 1-2, pp. 723-737.
Van Dyke, D. L. ; Weiss, L. / Maternal effect on intelligence of fragile X males and females. In: American Journal of Medical Genetics. 1986 ; Vol. 23, No. 1-2. pp. 723-737.
@article{124b2fa118c942ea944f161b099c53d4,
title = "Maternal effect on intelligence of fragile X males and females",
abstract = "If the mother is the fragile X gene carrier, her daughters (and sons) with the mutation are at high risk of mental retardation. If the father is the (clinically unaffected) carrier, his daughters are normal. This is strong evidence for a maternal effect. The decreased penetrance and variable expressivity in fra(X) offspring of carriers could be related, at least in part, to variable expression or availability of some maternal factor between pregnancies. We hypothesize a maternal effect in fra(X), with variability in intelligence of hererozygotes and hemizygotes mediated mainly by the maternal uterus or placenta by virtue of different patterns of lyonization in those tissues between pregnancies. If the mother is a carrier, the maternal placenta could develop with a skewed proportion of the normal or the fra(X) genetically active. Each female or male embryo could be exposed to very different environments with respect to genetic activity of the fra(X) chromosome, depending on the site of implantation within the uterus. If the father contributes the fra(X), the intrauterine environment is invariably normal and so are the daughters. Modifiers of the intrauterine effect could include lyonization patterns in tissues of the carrier fetus, and preferential inactivation of the paternal X in extra-embryonic tissues. The ultimate phenotype of the developing heterozygote and hemizygote may be determined by a threshold effect and interaction between the maternal genotype, the placental genotype, and the fetal genotype. The possibility of maternal effect is testable and has implications for treatment.",
author = "{Van Dyke}, {D. L.} and L. Weiss",
year = "1986",
language = "English (US)",
volume = "23",
pages = "723--737",
journal = "American Journal of Medical Genetics, Part A",
issn = "0148-7299",
publisher = "Wiley-Liss Inc.",
number = "1-2",

}

TY - JOUR

T1 - Maternal effect on intelligence of fragile X males and females

AU - Van Dyke, D. L.

AU - Weiss, L.

PY - 1986

Y1 - 1986

N2 - If the mother is the fragile X gene carrier, her daughters (and sons) with the mutation are at high risk of mental retardation. If the father is the (clinically unaffected) carrier, his daughters are normal. This is strong evidence for a maternal effect. The decreased penetrance and variable expressivity in fra(X) offspring of carriers could be related, at least in part, to variable expression or availability of some maternal factor between pregnancies. We hypothesize a maternal effect in fra(X), with variability in intelligence of hererozygotes and hemizygotes mediated mainly by the maternal uterus or placenta by virtue of different patterns of lyonization in those tissues between pregnancies. If the mother is a carrier, the maternal placenta could develop with a skewed proportion of the normal or the fra(X) genetically active. Each female or male embryo could be exposed to very different environments with respect to genetic activity of the fra(X) chromosome, depending on the site of implantation within the uterus. If the father contributes the fra(X), the intrauterine environment is invariably normal and so are the daughters. Modifiers of the intrauterine effect could include lyonization patterns in tissues of the carrier fetus, and preferential inactivation of the paternal X in extra-embryonic tissues. The ultimate phenotype of the developing heterozygote and hemizygote may be determined by a threshold effect and interaction between the maternal genotype, the placental genotype, and the fetal genotype. The possibility of maternal effect is testable and has implications for treatment.

AB - If the mother is the fragile X gene carrier, her daughters (and sons) with the mutation are at high risk of mental retardation. If the father is the (clinically unaffected) carrier, his daughters are normal. This is strong evidence for a maternal effect. The decreased penetrance and variable expressivity in fra(X) offspring of carriers could be related, at least in part, to variable expression or availability of some maternal factor between pregnancies. We hypothesize a maternal effect in fra(X), with variability in intelligence of hererozygotes and hemizygotes mediated mainly by the maternal uterus or placenta by virtue of different patterns of lyonization in those tissues between pregnancies. If the mother is a carrier, the maternal placenta could develop with a skewed proportion of the normal or the fra(X) genetically active. Each female or male embryo could be exposed to very different environments with respect to genetic activity of the fra(X) chromosome, depending on the site of implantation within the uterus. If the father contributes the fra(X), the intrauterine environment is invariably normal and so are the daughters. Modifiers of the intrauterine effect could include lyonization patterns in tissues of the carrier fetus, and preferential inactivation of the paternal X in extra-embryonic tissues. The ultimate phenotype of the developing heterozygote and hemizygote may be determined by a threshold effect and interaction between the maternal genotype, the placental genotype, and the fetal genotype. The possibility of maternal effect is testable and has implications for treatment.

UR - http://www.scopus.com/inward/record.url?scp=0022614825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022614825&partnerID=8YFLogxK

M3 - Article

C2 - 3513574

AN - SCOPUS:0022614825

VL - 23

SP - 723

EP - 737

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 0148-7299

IS - 1-2

ER -